Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $43.17

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYREGet Free Report) have received an average recommendation of “Buy” from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last year is $43.17.

SYRE has been the topic of several recent analyst reports. Robert W. Baird initiated coverage on shares of Spyre Therapeutics in a research note on Thursday, May 2nd. They issued an “outperform” rating and a $50.00 price target on the stock. BTIG Research raised their target price on shares of Spyre Therapeutics from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Stifel Nicolaus raised their target price on shares of Spyre Therapeutics from $36.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, March 26th. Finally, Wells Fargo & Company raised their target price on shares of Spyre Therapeutics from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, May 13th.

Read Our Latest Report on Spyre Therapeutics

Spyre Therapeutics Stock Up 1.4 %

SYRE stock opened at $25.79 on Wednesday. Spyre Therapeutics has a twelve month low of $2.66 and a twelve month high of $47.97. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -0.36 and a beta of 2.96. The firm’s fifty day simple moving average is $34.75 and its two-hundred day simple moving average is $29.77.

Spyre Therapeutics (NASDAQ:SYREGet Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, equities research analysts expect that Spyre Therapeutics will post -3.21 EPS for the current year.

About Spyre Therapeutics

(Get Free Report

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).

Recommended Stories

Analyst Recommendations for Spyre Therapeutics (NASDAQ:SYRE)

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.